Identiv Announces Stockholder Approval of Transaction with Security Solutions Provider Vitaprotech
Identiv announced that its stockholders approved the asset sale transaction with security solutions provider Vitaprotech, with over 96% of shares voting in favor at the Annual Meeting on June 28, 2024. The transaction, expected to close in Q3 2024, will secure $145 million for Identiv's growth in its IoT solutions business. This is aimed at accelerating RFID production transition to Thailand and enhancing technology and business development initiatives. The proposal saw a high voter turnout with about 72% of outstanding shares participating. Clearance from the Committee on Foreign Investment in the United States remains the last regulatory hurdle.
- Over 96% of shares voted in favor of the asset sale transaction.
- The transaction is set to secure a $145 million cash payment.
- High shareholder engagement with approximately 72% of outstanding shares voting.
- Accelerated RFID production transition from Singapore to Thailand.
- Enhanced technology, sales, and business development initiatives.
- None.
Insights
The approval of the asset sale transaction by Identiv's stockholders is quite significant, not only because 96% of shares voted in favor, but also due to the $145 million cash influx anticipated from the sale. This capital can be seen as a substantial boost for Identiv, particularly for their Internet of Things (IoT) business segment.
From a financial perspective, the influx will likely provide Identiv with the resources needed to accelerate the transition of RFID production from Singapore to Thailand. This relocation could help in cost optimization, taking advantage of lower labor costs and potentially better logistical positioning.
Additionally, the funds earmarked for technology, sales and business development initiatives can help Identiv establish a stronger foothold in the expanding IoT market. However, the reliance on regulatory approvals, such as from the Committee on Foreign Investment in the United States (CFIUS), poses a potential risk that investors should monitor closely. Any delays or issues in securing these approvals could push back the anticipated benefits.
The market dynamics for IoT solutions are evolving rapidly and Identiv's strategic decision to focus on this segment is timely. By securing the capital from the asset sale to Vitaprotech, Identiv is positioning itself to capture a larger share of the RFID-enabled IoT applications market. This sector is expected to grow significantly as industries increasingly adopt IoT technologies for better asset tracking and data collection.
It's important to highlight that the successful transition of production and the targeted investments in technology and sales can potentially enhance Identiv's competitive edge. However, the success of these initiatives hinges on their execution and the speed at which they can bring new products to market. Investors should be aware that while the long-term prospects look promising, the short-term impacts might be muted until these strategies start yielding tangible results.
Furthermore, the high level of stockholder support indicates strong confidence in the company's strategic direction, which could positively influence investor sentiment and stock performance in the short term.
Over
Company Poised to Close Strategic Transaction in Third Quarter of 2024, Securing Capital to Invest in the Growth of its IoT Solutions Business
The Company sought stockholder approval of the asset sale. Approximately
“On behalf of the Board of Directors, we would like to thank our stockholders for their support of the asset sale transaction,” said James Ousley, Chairman of the Board. “Having achieved this important milestone, we look forward to closing the transaction, which provides capital to support the future growth of our IoT business. This includes the accelerated transition of RFID production from
The detailed voting results are provided in the Current Report on Form 8-K filed with the SEC on July 2, 2024. The Company has previously received approval or cleared applicable waiting periods under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the United Kingdom National Security and Investment Act 2021. The only outstanding regulatory condition to closing is clearance from the Committee on Foreign Investment in
The transaction remains on track to close in the third quarter of 2024, as previously disclosed. Upon closing the transaction, Identiv will receive a cash payment of
About Identiv
Identiv, Inc. is a global leader in digitally securing the physical world. Identiv's platform encompasses RFID and NFC, cybersecurity, and the full spectrum of physical access, video, and audio security.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of management of Identiv and can be identified by words such as “anticipate,” “believe,” “continue,” “plan,” “will,” “intend,” “expect,” “outlook,” and similar references to the future. Any statement that is not a historical fact is a forward-looking statement, including statements regarding: the Company’s strategy, plans, initiatives and direction; the Company’s belief that the Annual Meeting voting results reflect high interest in and support of the Company’s strategic direction and maximizing value for its stockholders; the timing of the closing of the transaction; expected amount of proceeds from the transaction; and the terms and conditions related to the transaction, including regulatory approvals. Forward-looking statements are only predictions and are subject to a number of risks and uncertainties, many of which are outside Identiv’s control, which could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: the risk that the conditions to the closing of the transaction are not satisfied, including the risk that required regulatory approvals are not obtained; the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement; potential litigation relating to the transaction and the effects of any outcome related thereto; the ability of each party to consummate the transaction on a timely basis, or at all; the failure of the transaction to close for any reason; any purchase price adjustments to the amount of proceeds from the transaction; risks that the transaction disrupts current business, plans and operations of Identiv or its business prospects; diversion of management’s attention from Identiv’s ongoing business; the ability of Identiv to retain and hire key personnel; the effect of the change in management following the completion of the transaction; competitive responses to the transaction; costs, fees or expenses resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the transaction; Identiv’s ability to continue the momentum in its business; Identiv’s ability to successfully execute its business strategy; Identiv’s ability to satisfy customer demand and expectations; the loss of customers, suppliers or partners; the success of Identiv’s products and strategic partnerships; industry trends and seasonality; the impact of macroeconomic conditions and customer demand, inflation and increases in prices; and the other factors discussed in its periodic and other reports and documents filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240702645797/en/
Identiv Media Contact:
press@identiv.com
Identiv IR Contact:
IR@identiv.com
Source: Identiv, Inc.
FAQ
What was the outcome of Identiv's asset sale proposal with Vitaprotech?
When is the Identiv and Vitaprotech transaction expected to close?
How much capital will Identiv secure from the Vitaprotech transaction?
What percentage of Identiv's outstanding shares voted on the asset sale proposal?
What regulatory clearance is still required for Identiv's transaction with Vitaprotech?
What business areas will benefit from the capital raised through the Identiv-Vitaprotech transaction?
